| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 738 | 2015 |
| Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor SM Maira, S Pecchi, A Huang, M Burger, M Knapp, D Sterker, C Schnell, ... Molecular cancer therapeutics 11 (2), 317-328, 2012 | 596 | 2012 |
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012 | 594 | 2012 |
| Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ... Nature 518 (7538), 240-244, 2015 | 576 | 2015 |
| Single-vector inducible lentiviral RNAi system for oncology target validation D Wiederschain, W Susan, L Chen, A Loo, G Yang, A Huang, Y Chen, ... Cell cycle 8 (3), 498-504, 2009 | 473 | 2009 |
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials C Fritsch, A Huang, C Chatenay-Rivauday, C Schnell, A Reddy, M Liu, ... Molecular cancer therapeutics 13 (5), 1117-1129, 2014 | 472 | 2014 |
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh, C Costa, ... Cancer cell 26 (1), 136-149, 2014 | 442 | 2014 |
| Synthetic lethality as an engine for cancer drug target discovery A Huang, LA Garraway, A Ashworth, B Weber Nature reviews Drug discovery 19 (1), 23-38, 2020 | 375 | 2020 |
| Phosphatidylinositol 3-kinase α–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study D Juric, J Rodon, J Tabernero, F Janku, HA Burris, JHM Schellens, ... Journal of Clinical Oncology 36 (13), 1291, 2018 | 356 | 2018 |
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ... Science translational medicine 5 (196), 196ra99-196ra99, 2013 | 315 | 2013 |
| AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas M Elkabets, E Pazarentzos, D Juric, Q Sheng, RA Pelossof, S Brook, ... Cancer cell 27 (4), 533-546, 2015 | 309 | 2015 |
| Autosomal recessive retinitis pigmentosa caused by mutations in the α subunit of rod cGMP phosphodiesterase SH Huang, SJ Pittler, X Huang, L Oliveira, EL Berson, TP Dryja Nature genetics 11 (4), 468-471, 1995 | 298 | 1995 |
| A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling A Gaither, D Porter, Y Yao, J Borawski, G Yang, J Donovan, D Sage, ... Cancer research 67 (24), 11493-11498, 2007 | 281 | 2007 |
| Correlative analysis of genetic alterations and everolimus benefit in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer … GN Hortobagyi, D Chen, M Piccart, HS Rugo, HA Burris, KI Pritchard, ... Journal of Clinical Oncology 34 (5), 419-426, 2016 | 265 | 2016 |
| Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: a phase 1b clinical trial D Juric, F Janku, J Rodón, HA Burris, IA Mayer, M Schuler, ... JAMA oncology 5 (2), e184475-e184475, 2019 | 225 | 2019 |
| Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer C Costa, H Ebi, M Martini, SA Beausoleil, AC Faber, CT Jakubik, A Huang, ... Cancer cell 27 (1), 97-108, 2015 | 205 | 2015 |
| Re-establishing the regenerative potential of central nervous system axons in postnatal mice KS Cho, L Yang, B Lu, H Feng Ma, X Huang, M Pekny, DF Chen Journal of cell science 118 (5), 863-872, 2005 | 189 | 2005 |
| Molecular Cloning, Expression, and Characterization of a Novel Human Serine/Threonine Protein Phosphatase, PP7, That Is Homologous toDrosophila Retinal Degeneration C Gene … X Huang, RE Honkanen Journal of Biological Chemistry 273 (3), 1462-1468, 1998 | 177 | 1998 |
| An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin AP Garner, CU Bialucha, ER Sprague, JT Garrett, Q Sheng, S Li, ... Cancer research 73 (19), 6024-6035, 2013 | 138 | 2013 |
| Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6–Reactivating Rb in cancer. S Kim, A Loo, R Chopra, G Caponigro, A Huang, S Vora, S Parasuraman, ... Molecular Cancer Therapeutics 12 (11_Supplement), PR02-PR02, 2013 | 137 | 2013 |
